DE69940812D1 - Mekk1 serin threonin kinasen -fha forkhead verbundenes bereich -interagierendes protein 1 (mif1) - Google Patents

Mekk1 serin threonin kinasen -fha forkhead verbundenes bereich -interagierendes protein 1 (mif1)

Info

Publication number
DE69940812D1
DE69940812D1 DE69940812T DE69940812T DE69940812D1 DE 69940812 D1 DE69940812 D1 DE 69940812D1 DE 69940812 T DE69940812 T DE 69940812T DE 69940812 T DE69940812 T DE 69940812T DE 69940812 D1 DE69940812 D1 DE 69940812D1
Authority
DE
Germany
Prior art keywords
mif1
protein
gene
mekk
interaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940812T
Other languages
English (en)
Inventor
Christophe Marcireau
Marie-Christine Multon
Valerie Polard-Housset
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of DE69940812D1 publication Critical patent/DE69940812D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
DE69940812T 1998-07-21 1999-07-21 Mekk1 serin threonin kinasen -fha forkhead verbundenes bereich -interagierendes protein 1 (mif1) Expired - Lifetime DE69940812D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9359098P 1998-07-21 1998-07-21
PCT/EP1999/005142 WO2000005362A1 (en) 1998-07-21 1999-07-21 Mekk1(serine threonine kinases)-interacting fha (forkhead associated domain) protein 1 (mif1)

Publications (1)

Publication Number Publication Date
DE69940812D1 true DE69940812D1 (de) 2009-06-10

Family

ID=22239771

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940812T Expired - Lifetime DE69940812D1 (de) 1998-07-21 1999-07-21 Mekk1 serin threonin kinasen -fha forkhead verbundenes bereich -interagierendes protein 1 (mif1)

Country Status (10)

Country Link
EP (1) EP1100913B1 (de)
JP (1) JP4548938B2 (de)
AT (1) ATE430196T1 (de)
AU (1) AU764094B2 (de)
CY (1) CY1109289T1 (de)
DE (1) DE69940812D1 (de)
DK (1) DK1100913T3 (de)
ES (1) ES2326442T3 (de)
PT (1) PT1100913E (de)
WO (1) WO2000005362A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10020138A1 (de) * 2000-04-14 2001-10-31 Ulf R Rapp Nukleinsäure codierend für zumindest eine raf Teilsequenz mit einer MEKK1 Bindungsstelle
AU2002338732A1 (en) * 2001-09-19 2003-04-01 Medigene Ag Extracellular regulated kinase 2 (erk2)
CN117106090B (zh) * 2023-08-15 2024-02-09 十堰市太和医院（湖北医药学院附属医院） 一种靶向GSK3β的纳米抗体及其制备方法

Also Published As

Publication number Publication date
JP2002524026A (ja) 2002-08-06
CY1109289T1 (el) 2014-07-02
ATE430196T1 (de) 2009-05-15
WO2000005362A1 (en) 2000-02-03
EP1100913A1 (de) 2001-05-23
AU5505799A (en) 2000-02-14
PT1100913E (pt) 2009-08-03
AU764094B2 (en) 2003-08-07
EP1100913B1 (de) 2009-04-29
JP4548938B2 (ja) 2010-09-22
DK1100913T3 (da) 2009-08-24
ES2326442T3 (es) 2009-10-09

Similar Documents

Publication Publication Date Title
Gray et al. Aα and Bβ chains of fibrinogen stimulate proliferation of human fibroblasts
Couillard‐Despres et al. Doublecortin expression levels in adult brain reflect neurogenesis
Sumi et al. The expression of tissue and urokinase-type plasminogen activators in neural development suggests different modes of proteolytic involvement in neuronal growth
Yang et al. MCP-1 stimulates MMP-9 expression via ERK 1/2 and p38 MAPK signaling pathways in human aortic smooth muscle cells
Tournadre et al. Immature muscle precursors are a source of interferon‐β in myositis: role of Toll‐like receptor 3 activation and contribution to HLA class I up‐regulation
DK1051500T3 (da) Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme
Harley et al. Regulation by fibrinogen and its products of intercellular adhesion molecule-1 expression in human saphenous vein endothelial cells
Kishino et al. Pancreatic-type phospholipase A2 induces group II phospholipase A2 expression and prostaglandin biosynthesis in rat mesangial cells.
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
DE69739480D1 (de) Menschliche hämatopoietische stamm und vorläuferzellantigen und methoden zu dessen verwendung
DK0914345T3 (da) Antistoffer, som binder til monocyt-kemoattraktant-protein-1-receptor (MCP-1-receptor) (CCR2)
YU83600A (sh) Adenozin a3 receptorski modulatori
BR9806954A (pt) Receptores 6a e 6b do fator de necrose tumoral
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
DE69521608D1 (de) Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl-antikörperzubereitung
BR0211614A (pt) polipeptìdeo tacis e br3 e empregos dos mesmos
ATE476654T1 (de) Plattform für protein-profiling
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
WO2005010215A3 (en) Methods for identifying tolerance modulatory compounds and uses therefor
WO2002063271A3 (en) Activity based probe analysis
Kubo et al. Distinct activity of peptide mimetic intracellular ligands (Pepducins) for proteinase‐activated receptor‐1 in multiple cells/tissues
CY1109289T1 (el) Αλληλεπιδραση κινασων μεκκ1 σερινης θρεονινης με το σχετιζομενο με το fha forkhead πεδιο της πρωτεϊνης 1 (mif 1)
Shiga et al. Characteristic phenotype of immortalized periodontal cells isolated from a Marfan syndrome type I patient
Brandan et al. Extracellular matrix components and amyloid in neuritic plaques of Alzheimer's disease.
ATE404865T1 (de) T zell-subpopulation zur regelung der darmimmunität

Legal Events

Date Code Title Description
8364 No opposition during term of opposition